Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Prevention of acute sickle cell crisis: review of the NEJM report
source: Practical Pain Management
year: 2016
authors: Leonard Goldstein, Victoria A. Troncoso, Roya Vahdatinia
summary/abstract:A recent article in the New England Journal of Medicine presented the results of a phase 2 clinical trial that found positive results for the efficacy and safety of crizanlizumab, a novel pharmaceutical agent currently in pipeline development by Selexys Pharmaceuticals.
The drug, designed to block the underlying mechanism of acute painful crisis in patients suffering from sickle-cell disease, could be one of the first and most effective medications of its kind. For all the details on the Phase 2 research, read the original Practical Pain Management report.
In this commentary, Leonard B. Goldstein, DDS, PhD, and colleagues review the research and provide their own opinion on the prospect of a novel pharmaceutical agents for patients suffering from sickle cell disease.
read more
Related Content
-
Evaluation of Macular Vascular Abnormalities Identified by Optical Coherence Tomography Angiography in Sickle Cell D...PURPOSE: To evaluate macular vascular fl...
-
Practice variation in emergency department management of children with sickle cell disease who present with feverOBJECTIVES:Urgent medical evaluation is ...
-
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study FindsHydroxyurea, a treatment recommended for...
-
Living With Sickle Cell Disease: One Person’s Story of Pain and Prejudice and Their Hopes for a Stem Cell TherapyMy name is Marissa Cors, I have sickle c...
-
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell DiseaseMaxCyte, a US-based global company dedic...
-
Johns Hopkins researchers offer new protocol to potentially cure sickle cell diseaseThere's new hope for patients who have b...
-
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.